JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 1991; 18:1804-1810
© 1991 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Torr,
Right arrow Articles by Abendschein, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Torr, , SR
Right arrow Articles by Abendschein, D.

Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factor

Torr SR, EJ Haskel, PF VonVoigtlander, Bergmann SR, and DR Abendschein

Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri 63110.

To determine whether platelet-activating factor is a specific mediator of cyclic flow variations in damaged stenotic arteries and whether it contributes to reocclusion after thrombolysis, femoral arteries in anesthetized dogs were subjected to mural injury and high grade stenosis to induce cyclic flow variations (28 +/- 4/h) or methods selected to elicit platelet-rich and fibrin-rich thrombosis. Oral administration of a novel triazolobenzodiazepine (U46,195 [10 mg/kg]) that selectively inhibits platelet-activating factor abolished cyclic flow variations within 120 min and for greater than or equal to 2 h thereafter compared with persistent flow variations in dogs given saline solution. Platelet aggregation induced ex vivo with platelet-activating factor was inhibited in parallel with in vivo inhibition of cyclic flow variations after administration of U46,195. However, buccal mucosa bleeding time was not affected. After thrombosis, administration of U46,195 before thrombolysis was induced with human recombinant tissue-type plasminogen activator (1.7 mg/kg intravenously over 60 min) prevented reocclusion within 120 min in six of eight and six of seven arteries by platelet-rich and fibrin-rich thrombosis, respectively. In contrast, in dogs given saline solution, reocclusion occurred in eight of eight (p = 0.007 compared with U46,195) and five of eight arteries by platelet-rich and fibrin-rich thrombosis, respectively. Thus, both cyclic flow variations and reocclusion after thrombolysis appear to be mediated in part by platelet-activating factor. The results suggest that inhibition of platelet-activating factor with specific antagonists may be useful in reducing platelet-mediated occlusion of coronary arteries without eliciting bleeding.


This article has been cited by other articles:


Home page
CirculationHome page
H. Arakawa, J.-Y. Qian, D. Baatar, K. Karasawa, Y. Asada, Y. Sasaguri, E. R. Miller, J. L. Witztum, and H. Ueno
Local Expression of Platelet-Activating Factor-Acetylhydrolase Reduces Accumulation of Oxidized Lipoproteins and Inhibits Inflammation, Shear Stress-Induced Thrombosis, and Neointima Formation in Balloon-Injured Carotid Arteries in Nonhyperlipidemic Rabbits
Circulation, June 21, 2005; 111(24): 3302 - 3309.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. Montrucchio, G. Alloatti, and G. Camussi
Role of Platelet-Activating Factor in Cardiovascular Pathophysiology
Physiol Rev, October 1, 2000; 80(4): 1669 - 1699.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
K. Fujise, L. Stacy, P. Beck, E. T.H. Yeh, A. Chuang, T. A. Brock, and J. T. Willerson
Differential Effects of Endothelin Receptor Activation on Cyclic Flow Variations in Rat Mesenteric Arteries
Circulation, November 18, 1997; 96(10): 3641 - 3646.
[Abstract] [Full Text]


Home page
CirculationHome page
G. Montrucchio, E. Lupia, A. De Martino, L. Silvestro, S. R. Savu, G. Cacace, P.G. De Filippi, G. Emanuelli, and G. Camussi
Plasmin Promotes an Endothelium-Dependent Adhesion of Neutrophils : Involvement of Platelet Activating Factor and P-Selectin
Circulation, June 15, 1996; 93(12): 2152 - 2160.
[Abstract] [Full Text]


Home page
Circ. Res.Home page
H. W. Mueller, C. A. Haught, J. M. McNatt, K. Cui, S. J. Gaskell, D. A. Johnston, and J. T. Willerson
Measurement of Platelet-Activating Factor in a Canine Model of Coronary Thrombosis and in Endarterectomy Samples From Patients With Advanced Coronary Artery Disease
Circ. Res., July 1, 1995; 77(1): 54 - 63.
[Abstract] [Full Text]


Home page
CirculationHome page
H. S. Demrow, P. R. Slane, and J. D. Folts
Administration of Wine and Grape Juice Inhibits In Vivo Platelet Activity and Thrombosis in Stenosed Canine Coronary Arteries
Circulation, February 15, 1995; 91(4): 1182 - 1188.
[Abstract] [Full Text]


Home page
HypertensionHome page
W. H. Beierwaltes, D'A. L. Potter, O. A. Carretero, and D. H. Sigmon
Nitric Oxide Synthesis Inhibition Blocks Reversal of Two-Kidney, One Clip Renovascular Hypertension After Unclipping
Hypertension, February 1, 1995; 25(2): 174 - 179.
[Abstract] [Full Text]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1991 by the American College of Cardiology Foundation.